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Jörg Rohde1,2, Frederic Emschermann2, Michael R Knittler2† and Hanns-Joachim Rziha1,2*†Abstract
Background: The Orf virus (ORFV), a zoonotic Parapoxvirus, causes pustular skin lesions in small ruminants (goat
and sheep). Intriguingly, ORFV can repeatedly infect its host, despite the induction of a specific immunity. These
immune modulating and immune evading properties are still unexplained.
Results: Here, we describe that ORFV infection of permissive cells impairs the intracellular transport of MHC class I
molecules (MHC I) as a result of structural disruption and fragmentation of the Golgi apparatus. Depending on the
duration of infection, we observed a pronounced co-localization of MHC I and COP-I vesicular structures as well as
a reduction of MHC I surface expression of up to 50%. These subversion processes are associated with early ORFV
gene expression and are accompanied by disturbed carbohydrate trimming of post-ER MHC I. The MHC I
population remaining on the cell surface shows an extended half-life, an effect that might be partially controlled
also by late ORFV genes.
Conclusions: The presented data demonstrate that ORFV down-regulates MHC I surface expression in infected cells
by targeting the late vesicular export machinery and the structure and function of the Golgi apparatus, which
might aid to escape cellular immune recognition.
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The Orf virus (ORFV; Parapoxvirus ovis) is the type spe-
cies of the Genus Parapoxvirus belonging to the family
Poxviridae. It is a skin epitheliotropic double-stranded
DNA virus that causes pustular skin lesions in sheep and
goats, known as contagious ecthyma [1]. Most interest-
ingly, animals are not protected against ORFV re-
infections, which might also be due to the short-lived
ORFV-specific adaptive immunity. Orf is a zoonotic dis-
ease [2] that can be transmitted to humans by contact
with infected animals. While Orf is usually a benign self-
limiting illness, it can be very progressive in immune-
compromised hosts [2].* Correspondence: achim.rziha@fli.bund.de
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reproduction in any medium, provided the orPoxviruses provide considerable inventories of gene pro-
ducts that allow them to evade the host immune response
[3]. It has been previously shown that ORFV encodes
immunomodulators like ORFV IL-10, the GM-CSF- and
IL-2-inhibitory factor (GIF) or the ORFV chemokine bind-
ing protein CBP, which have the ability to inhibit cytokine
synthesis of monocytes [4-8]. These evasion strategies
seem to play an important role in supporting ORFV repli-
cation and enabling repeated re-infections.
Cell-mediated immunity is critical for the clearance of
virus-containing cells. Infected hosts normally react by ac-
tivating their MHC I - mediated cellular immune response
[9]. MHC I transmembrane glycoproteins function by
binding intracellularly processed peptide antigens and pre-
senting them on the cell surface to cytotoxic T cells [10].
During viral infection, a spectrum of antigenic peptides is
displayed by MHC I molecules, resulting in the specific
recognition of the infected cells by cytotoxic T cells (CTL).
However, many viruses, including poxviruses [3,11], evade
the T cell-mediated immune response, primarily byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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presentation of pathogen-derived antigens [12] to escape
cellular immunosurveillance mechanisms [13]. MHC I
down-regulation of infected cells increases susceptibility
to natural killer (NK) cells, and many viruses have also
evolved strategies to escape this immune detection [14].
The ability to inhibit proinflammatory cytokines (TNF
and IFN) that regulate MHC expression is a mechanism
of poxviruses to prevent the up-regulation of MHC I [3].
The gene product M153R of myxoma virus interferes
directly with the antigen presentation pathway and
induces the loss of β2-microglobulin associated MHC I,
both at the cell surface and in an intracellular post-Golgi
compartment [15]. Genes of cowpox virus modulate the
MHC I antigen processing and expression. The
CPXV203 protein is responsible for decreased surface
expression of mouse and human MHC I molecules by
using the physiologic KDEL-pathway to retain MHC I in
the ER [16,17], whereas the CPVX12 protein prevents
TAP-dependent peptide loading [18,19].
We are interested to identify possible immune evasion
mechanisms of ORFV, the type species of Parapoxvirus.
Also in vitro propagation of wild-type ORFV is very
restricted and mostly primary ovine or bovine cells are
used, which limits the availability of MHC I or cell com-
partment specific reagents. Therefore, we took advantage
from the Vero cell-adapted ORFV strain D1701-V to ana-
lyse virus induced alterations of MHC I surface expression
in infected permissive Vero cells. We show that this Para-
poxvirus impairs MHC I surface expression by structurally
disrupting the Golgi apparatus. Most interestingly, Golgi
fragmentation is accompanied by a defective intracellular
MHC I transport, pronounced co-localization of MHC I
and COP-I-vesicles, disturbed carbohydrate trimming of
Golgi-localized MHC I molecules and a reduction of
MHC I surface expression of up to 50%. In addition to
these effects, we also noticed that the half-life of the
remaining MHC I surface population is remarkably
increased. All observed evasion phenotypes except for the
MHC I half-life effect are linked to the expression of early
ORFV genes. On the basis of our findings we postulate
that ORFV modulates MHC I surface expression in
infected cells by targeting the vesicular transport machin-
ery and the structure and function of the Golgi apparatus.
Thus, it is tempting to speculate that the discovered
ORFV-mediated effects on MHC I act in concert to facili-
tate infection and allow the acute virus to replicate and
shed prior to clearance by the host immune response.
Results
ORFV induces down-regulation of surface MHC I
molecules
Surface expression of MHC I was investigated in ORFV-
infected and non-infected Vero cells by flow cytometryusing the MHC I specific monoclonal antibody (mAb)
W6/32 as described in Methods. As shown in Figure 1a,
ORFV infection resulted in a significant decrease of the
MHC I surface expression. Twelve hours post infection
(hpi) about 80% of MHC I was detectable on the cell
surface compared to non-infected cells, which was fur-
ther reduced to 70% at 24 hpi, and to almost 50% at 36
hpi. These decreases were statistically highly significant
as determined by One-way ANOVA analysis (P< 0.001).
Reduction of MHC I surface expression was dependent
on live, replicating ORFV. Thus, infection of the cells
with β-propiolactone-inactivated virus did not change
the amount of MHC I expressed on the surface of Vero
cells (Figure 1a, inact. ORFV).
To analyze whether expression of early or late ORFV
genes might be responsible for the MHC I down-
regulation, AraC was used to inhibit viral DNA synthesis
and thereby preventing intermediate and late gene ex-
pression of ORFV [6]. Figure 1b demonstrates that
blocking of ORFV intermediate and late gene transcrip-
tion (+ AraC) did not abolish MHC I down-regulation
or affect MHC I surface presentation in non-infected
cells. Infection of Vero cells and the effect of AraC were
controlled by immunofluorescence studies using the
mAb 13 C10, which is directed against the late major
envelope protein of ORFV (Figure 1e).
ORFV infection increases the half-life of remaining surface
MHC I molecules
Virus-infected cells were treated with Brefeldin A (BFA) to
examine the biological stability of cell surface expressed
MHC I molecules. BFA prevents the anterograde MHC I
transport from the endoplasmic reticulum (ER) to the
Golgi apparatus, and thereby inhibits the supply of newly
synthesized MHC I to the cell surface. This experimental
design allows the analysis of the half-life of surface
expressed pre-existing MHC I by using flow cytometry.
BFA-treated, non-infected Vero cells showed a 40 and
60% reduction of surface MHC I after 8 and 20 h incuba-
tion, respectively (Figure 1c, ni). In contrast, virus-infected
Vero cells showed at the same BFA-incubation time points
only a marginal MHC I decrease of 10% and 30%
(Figure 1c, ORFV). These results suggest that ORFV infec-
tion increases the half-life of the remaining MHC I surface
population by affecting surface stability and/or recycling
of MHC I molecules. To examine whether early and/or
late ORFV gene expression might be responsible for the
increase in MHC I surface survival, cells were additionally
treated with AraC during ORFV infection and BFA treat-
ment. Figures 1c, d show that the MHC I half-life on the
surface of non-infected cells was not altered by AraC. In
infected cells the presence of AraC has some neutralizing
influence on the ORFV mediated half-life effect on surface
MHC I (compare Figure 1c, d). Thus, the ORFV-
Figure 1 Modulation of MHC I surface expression in ORFV-infected cells. (A) Vero cells were harvested at 12, 24, and 36 hpi (m.o.i. 1.0) and
stained with the anti-MHC I mAb W6/32 as described in Methods. The effect of non-replicating ORFV was tested by the use of ß-propiolactone
inactivated ORFV (inact. ORFV; m.o.i. 1.0 before inactivation), non-infected (ni) cells were used as negative controls. The average of three separate
virus culturing experiments is shown. ORFV infection decreased cell surface expressed MHC I. (B) Twenty hours post infection (m.o.i. 1.0), MHC I
cell surface expression (W6/32) was determined by FACS in the presence and absence of AraC. No effect of AraC treatment on MHC I surface
expression was observed. One representative experiment is shown. (C) ORFV infected (m.o.i. 1.0) or non-infected Vero cells were treated with BFA
or (D) with BFA plus AraC. Virus infection increased the half-life of MHC I on the cell surface, determined at 8, 12 and 20 hpi using W6/32 anti-
MHC I antibody by flow cytometry. The average of three independent experiments is shown in C, D. The relative mean fluorescence intensity (rel
MFI) is given in percentages. (E) Infection (m.o.i. 1.0) of Vero cells (green staining) and the effect of AraC was controlled (24 hpi) by
immunofluorescence studies using the mAb 13 C10 (diluted 1:1000) recognizing the late major envelope protein of ORFV. Nuclei and F-actin are
stained blue by DAPI and white by phalloidin-TRITC, respectively.
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partially controlled also by late gene products.
ORFV infection does not influence MHC I-transcription
A semi-quantitative RT-PCR was used to determine
whether ORFV infection might influence the MHC I
mRNA synthesis and thereby reduces MHC I surfaceexpression. The amount of mRNA specific for the
housekeeping gene GAPDH was related to the amount
of MHC I mRNA at different times after infection. Each
PCR product taken at the linear phase of PCR amplifica-
tion was analyzed by gel densitometry. As shown in
Figure 2a, the ratio of MHC I to GAPDH mRNA in
non-infected cells ranged between 0.63 and 0.65 (Lanes
Figure 2 Effects of ORFV-infection on expression and intracellular transport of MHC I . (A) MHC I- and GAPDH-specific RT-PCR was
performed as described in Methods. After gel electrophoresis the amplicon band intensities were quantified by densitometry and their calculated
ratios are indicated below each gel lane. The transcription rate of MHC I was not affected significantly by ORFV infection. (B, upper panel) ORFV
infection affects carbohydrate trimming of MHC I. Infected (+; m.o.i. 2.0) or not infected (−) cells were labelled with Trans-35 S-Label, lysed at 12,
24 and 36 hpi, and MHC I was immunoprecipitated with W6/32 antibody. The immunoprecipitates were digested with Endo H before separation
by SDS-PAGE. Fluorographs were analyzed using GelEval 1.32 software (FrogDance Software). Endo H-resistant, -sensitive and partially Endo H-
resistant MHC I forms are indicated. (B, lower panel) Infected (+; m.o.i. 1.0) or not infected (−) cells were lysed at 12 hpi, digested with Endo H
and analyzed by Western blots probed with anti-MHC I mAb LY5.1.
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after ORFV infection (lanes 1 and 3). Thus, the observed
decrease of MHC I surface expression cannot be attribu-
ted to a prevention or inhibition of MHC I mRNA tran-
scription by ORFV.
ORFV infection disturbs carbohydrate trimming and
maturation of MHC I
Next we analyzed whether and to what extent intracel-
lular maturation of MHC I along the secretory route
might be affected by ORFV infection. Endoglycosidase
H (Endo H) – cleavage experiments were performed
with anti-MHC I immunoprecipitates from detergent
extracts of biosynthetically labelled, infected or non-
infected Vero cells. Endo H is used to monitor posttran-
slational modification of glycosylated proteins within
the Golgi. The MHC I-attached high mannose oligosac-
charides are modified by a series of different ER andGolgi enzymes. Endo H is able to cleave oligosacchar-
ides until the medial Golgi enzyme α-mannosidase II
removes two mannose subunits. Since all later carbohy-
drate structures are Endo H-resistant, the enzyme
monitors MHC I maturation within the late secretory
route.
As can be seen from the SDS-PAGE analysis in
Figure 2b upper panel, 12 h after ORFV infection intra-
cellular MHC I-maturation is comparable in infected
and non-infected Vero cells. In both situations we
observed an approximately 1:1 signal ratio between Endo
H-sensitive and -resistant MHC I molecules (Figure 2b
upper panel, compare lanes 1 and 2). An additional
minor species (approximately 10% of total MHC I signal)
of partially resistant MHC I was also visible in infected
cells (Figure 2b, upper panel, lane 2). After 24 and 36 h
of infection, the population of Endo H-resistant MHC I
was almost unaffected whereas the amount of Endo H-
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upper panel, lanes 4 and 6) as determined by
densitometric scanning. Most importantly, the latter
phenomenon was linked to a simultaneous increase of
partially Endo H-resistant MHC I molecules by 45 and
55%, respectively. No such formation of unusual MHC I
forms could be observed for non-infected control cells
after 24 or 36 h of incubation (Figure 2b, upper panel,
compare lanes 1, 3 and 5). The distinct behaviour of
MHC I maturation in ORFV-infected cells was also seen
in Western blot experiments, in which lysates of infected
and non-infected Vero cells were assayed by using a dif-
ferent anti-MHC I antibody (mouse mAb, clone LY5.1,
see Figure 2b, lower panel) with apparently higher speci-
ficity for the mature forms of MHC I. The two Endo H-
resistant and -sensitive protein bands found after immu-
noprecipitation (Figure 2b, upper panel) or in Western
blotting (Figure 2b, lower panel) by the two different
anti-MHC I antibodies (W6/32 and LY5.1) most likely
represent different allelic MHC I products expressed in
Vero cells. Taken together, these findings suggest that
ORFV-infection interferes with the functional require-
ments for proper carbohydrate trimming of MHC I
within the cis- and/or medial-Golgi or the transport be-
tween the exocytic compartments.
ORFV infection results in morphological changes of the
Golgi apparatus
Next, we investigated whether ORFV infection might
affect the secretory pathway and Golgi transport of
MHC I and thereby prevents intracellular trafficking of
newly synthesized MHC I to the cell surface. Therefore,
we analyzed infected cells by confocal immunofluores-
cence after co-staining of intracellular MHC I and Gian-
tin, a main component of the cis- and medial-Golgi. The
results in Figure 3a demonstrate that virus infection
caused substantial changes in the localization patterns of
MHC I and Giantin. Already 10 hpi, MHC I dispersed
into the cytoplasm with a punctuated vesicular structure
(Figure 3a - panel A) continuing to 24 hpi (Figure 3a -
panel G), whereas MHC I in non-infected Vero cells
showed a dense and ring-shaped perinuclear staining
(Figure. 3a - panels D and J).
In non-infected cells, Giantin-staining was character-
ized by a compact perinuclear pattern (Figure 3a -
panels E and K) that disappeared during ORFV infection
and scattered throughout the cytoplasm (Figure 3a -
panels B and H). Simultaneously, co-localization be-
tween Giantin and MHC I, which was clearly seen in
non-infected cells (Figure 3a - panels F and L), was
reduced during virus infection (Figure 3a – panels C and
I) as verified by calculating the coefficient of co-
localization (Pearson value; data not shown). The
ORFV-induced Golgi spreading was also found in AraC-treated infected cells (Figure 3a, panels M to R)
indicating the involvement of early ORFV gene(s). The
ORFV-induced dislodgment of Golgi from its original
nucleus-associated location into the cytoplasm could be
confirmed by quantitative analysis of the distances be-
tween Golgi and nucleus in infected and non-infected
cells (Figure 3b). The distance from the centre of the nu-
cleus of each cell to the peripheral fringe of the Golgi
was almost duplicated in infected cells, in the presence
as well as in the absence of AraC, when compared to
non-infected cells, and was highly significant according
to T test (P< 0.0001).
The trans-Golgi network (TGN) represents another
important constituent of the late secretory route
involved in exo- as well as endocytic processes [20]. The
possible influence of ORFV on the TGN structure was
examined with a TGN46-specific antibody. Partial co-
localization between TGN46 and MHC I was visible in
infected and non-infected cells. Similar to Giantin and
MHC I, TGN46 lost its prominent perinuclear distribu-
tion after virus infection in favour of a punctuated ves-
icular pattern within the cytoplasm (Figure 4a, compare
panels A and D, B and E), which was also seen in
infected cells arrested for early gene expression by AraC
(data not shown). Quantitative analysis of the images
(Figure 4b) revealed a significantly increased distance (P
< 0.0001) between TGN and nucleus (17 to 23 μm) in
comparison to non-infected cells (9 to 12 μm). In sum-
mary, in virus infected cells Golgi and TGN are structur-
ally dispersed into the cytoplasm and these processes are
linked to early gene expression.
Influence of ORFV on the intracellular transport of MHC I
molecules
Since ORFV-infection leads to a fragmentation of Golgi,
we explored the viral influence on Golgi-transport of
MHC I. COP-I is a protein complex that coats vesicles
transporting polypeptides between different Golgi com-
partments and from the cis-Golgi back to the ER [21].
Therefore, we analyzed intracellular staining of MHC I
and COP-I-component β-COP in infected and non-
infected cells by fluorescence microscopy. Non-infected
Vero cells displayed a characteristic juxtanuclear staining
pattern of MHC I (Figure 5a - panels D and J) but only
partial intracellular co-labelling of MHC I and β-COP
(Figure 5a - panels F and L). In infected Vero cells a prom-
inent perinuclear and vesicular MHC I-staining was
observed 10 hpi that, however, dispersed into the cyto-
plasm after 24 hpi (Figure 5a - panels A and G). In con-
trast to non-infected cells, MHC I/β-COP co-localization
could be seen for both infection time points (Figure 5a -
panels C and I) confirmed by Pearson value calculation
(data not shown). It must be noted that the non-infected
cells were photographed with longer exposure time for
Figure 3 ORFV-induced dispersion of the Golgi apparatus. (A) Vero cells were infected (m.o.i. 0.5) and stained with the MHC I-specific mAb
W6/32 (green) and the Giantin antibody specific for Golgi (red) after 10 hpi (panels A-F) and 24 hpi (panels G-L) or 24 hpi in the presence of
AraC (panels M-R). In infected cells MHC I dispersed into the cytoplasm and Golgi structures dispersed into the cytoplasm. Nuclei are stained
blue by DAPI. Representative results of five independent experiments are shown. (B) The distances of the Golgi from the nucleus in non-infected
and infected cells in the presence or absence of AraC were quantified using with AxioVision Rel. 4.8 software. The evaluation of 46 infected cells
(ORFV), 20 infected and AraC-treated cells (ORFV/AraC), and 42 non-infected cells (ni) demonstrates significantly (T test: P< 0.0001) increased
distance between Golgi and cell nucleus in infected cells. Box plots with median percentile were accomplished with GraphPad Prism 5 software.
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ments showed that this effect is also controlled by early
ORFV gene expression (data not shown).Given expression levels of β-COP were analyzed by
Western blot experiments in infected and non-infected
cells. Figure 5b demonstrates that the 95 kDa β-COP
Figure 4 Structural changes of the trans-Golgi network (TGN) after ORFV infection. (A) Infected cells (m.o.i. 0.5) or non-infected cells were
fixed 24 hpi and stained with W6/32 antibody (green) and anti-TGN46 antibody (red) (panels A-F). Partial co-localization of MHC I and TGN can
be seen in infected cells by merging the fluorescent images (merge). Nuclei are stained blue by DAPI. After infection TGN lost its perinuclear
location and moved into the cytoplasm. A representative result of confocal fluorescence microscopy of three experiments is shown. (B) TGN-
dislocation in ORFV infected cells. The distances of the TGN and the nucleus in infected and non-infected cells were quantified using with
AxioVision Rel. 4.8 software (Zeiss). The evaluation of 27 infected and 27 non-infected cells is summarized as box plots and demonstrates an
increased distance between TGN and cell nucleus in infected cells.
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infected Vero cells, most likely due to the fact that β-
COP, like other COP-I components, does not stably exist
out of the coatomer complex [22]. Nevertheless, 24 h
after ORFV infection β-COP was clearly visible with
reduced amounts expressed after 36 hpi suggesting that
the population of stably assembled COP-I structures is
drastically enlarged in infected cells. Comparable protein
loading was controlled by β-actin staining (Figure 5b,
lower panel). Taken together, our findings provide evi-
dence that the amount of MHC I-containing stable
COP-I vesicles increased significantly during the first 24
hours after ORFV infection.
Discussion
The presented study shows that cellular ORFV infection
leads to structural dispersion of the Golgi/TGN com-
partments and enrichment of COP-I vesicular structures.
These processes are accompanied by an increase in thesteady state expression of β-COP (Figure 5b), defective
carbohydrate trimming of MHC I within the Golgi
(Figure 2b), reduction of surface expressed MHC I mole-
cules and a prolonged half-life of pre-existing MHC I on
the plasma membrane (Figure 1). Upcoming studies have
to prove whether the described interferences of ORFV
with the MHC I expression also occur in natural host
cells.
Our findings demonstrate that in ORFV-infected cells
the intra-Golgi- and endosome/TGN-transport of MHC
I was severely disturbed. ORFV seems to utilize early
gene expression to block MHC I export within the late
secretory route and thereby reduces MHC I surface ex-
pression. As shown by our experiments ORFV alters the
perinuclear localization as well as the overall structure
of the Golgi and TGN in infected Vero cells. Similar
effects on the Golgi have also been described for a var-
iety of different viruses. Early gene expression of Vari-
cella zoster virus leads to MHC I down-regulation by
Figure 5 ORFV-infection interferes with COP-I mediated vesicular transport. (A) MHC I co-localizes with COP-I vesicles after ORFV infection.
In infected cells (m.o.i. 0.5) MHC I was stained with mAb W6/32 (green) and anti-β-COP antibody (red). A representative result of three
experiments at 10 hpi (panels A-F) and 24 hpi (panels G-L) is shown. Cell nuclei are stained blue with DAPI. A distinct co-localization (merge,
yellow) of MHC I and β-COP was found in infected cells. Note that non-infected cells had to be photographed with longer exposure times as
infected cells for the sake of better MHC-I/ß-COP visualization. (B) ORFV induced expression levels of β-COP. ß-COP (95 kDa) was detectable by
Western blot analysis in infected cells (m.o.i. 1.0; lanes +) during 24 to 36 hpi. Detection of cellular ß-actin demonstrates comparable protein
loading.
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event in the reproductive cycle of Herpes simplex virus
type 1 causes fragmentation and dispersal of the Golgi in
infected Vero cells, which coincides with virion assembly
[24]. The infection with human rhinovirus 1A (HRV-1A)
induces Golgi-fragmentation into vesicles that appear to
be used as a substrate for viral RNA replication [25].
Another positive-strand RNA virus, the poliovirus,
induces dramatic disruption of the Golgi with conse-
quences for the secretory complex [26,27]. Furthermore,
it is known that vaccinia virus becomes enwrapped by
cisternae derived from the intermediate compartmentbetween ER and Golgi stacks as well as the TGN [28].
Recently Tan et al. also observed fragmentation of the
Golgi during ORFV infection, and reported the Golgi
localization of an ORFV envelope protein during late
stage of infection [29]. The authors suggested that it is
concealed between two Golgi membranes, which are
forming wrapped mature virions. In the present study,
the destruction of the Golgi structure is clearly not
linked to virus envelope formation since the observed
structural modifications are also visible in the presence
of AraC, which prevents the expression of late ORFV
genes essentially required for the virus envelope.
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amount of newly synthesized MHC I on the plasma
membrane as well as a prolonged half-life of the
remaining pre-existing surface MHC I molecules
(Figure 1). Down-regulation of MHC I is clearly AraC-
insensitive and thus apparently linked to the expression
of early ORFV genes whereas it cannot be excluded that
the observed MHC I half-life effect might be also con-
trolled by late ORFV gene expression. It is tempting to
speculate that the respective viral gene products target
compartments within the late secretory route. Since
structural and functional integrity of the TGN are
essentially required for endosomal/TGN-trafficking,
the observed disruption of the TGN in infected cells
(Figure 4) might be suspected to interfere with endo-
cytosis as well as endosomal recycling of MHC I. A simi-
lar phenotype has been described for the HPV16 protein
E5 [30], which mediates disruption of the exo- and
endocytic trafficking, including transport of the MHC I
[30], which causes reduced MHC I surface presentation
and extends the half-life of the remaining MHC I mole-
cules on the plasma membrane (M. R. Knittler, manu-
script in preparation).
The ORFV infection leads to an accumulation of
MHC I in COP-I vesicles (Figure 5a). COP-I is the cyto-
plasmic membrane-coat complex (coatomer) of seven
distinct proteins and is required for both anterograde
and retrograde transport in the secretory pathway
[31,32]. The observation that ORFV infection increases
the cellular expression levels of β-COP (Figure 5b) and
the amount of COP-I vesicular structures suggests inhib-
ition of uncoating of COP-I vesicles by ORFV. The iden-
tification of responsible ORFV protein(s), as found in
Coxsackievirus [33], requires further detailed studies. In
contrast to vaccinia virus, which hijacks the COP-I coat-
omer for viral particle formation [34], no correlation
between accumulation of COP-I vesicles and viral bio-
genesis was observed, since the ORFV-mediated effect
was also detectable in the presence of AraC.
The Endo H-experiments suggest that destruction of
Golgi and TGN structures as well as intracellular accu-
mulation of MHC I in COP-I vesicles is accompanied by
impaired post-ER maturation of the N-linked carbohy-
drates of MHC I. In contrast to non-infected cells, a
substantial amount of the MHC I molecules exhibits
partial Endo H-resistance in ORFV-infected cells indicat-
ing that these molecules are not correctly processed by
carbohydrate-trimming within Golgi. This reminds of
the defective maturation of MHC I in the presence Con-
canamycin B, a specific inhibitor of the vacuolar type H
(+)-ATPase [35], suggesting that ORFV infection not
only affects the intracellular location and structure of
Golgi and TGN, but also the functional pH conditions
within these two compartments.In addition to MHC I, ORFV infection also interferes
with the surface expression of the transferrin receptor
(TfR, CD71) (data not shown), which suggests that the
ORFV-induced reduction of MHC I-antigen presenta-
tion is mediated by subversion of the host cell export
machinery and not via specific targeting of MHC I mole-
cules. Thus, one could assume that the ORFV-mediated
modulation of vesicular transport has a more pleiotropic
effect that also includes the reduction of antigen presen-
tation and thereby provides an immune subversion strat-
egy in advantage of the viral pathogen.
ORFV does clearly not interfere with the expression of
MHC I molecules (Figure 2a) but uses an evasion strat-
egy that accumulates newly synthesized MHC I mole-
cules within the late secretory pathway (COP-I vesicles)
possibly to down-modulate MHC I presenting viral anti-
gens (for evasion of a cytotoxic T cell -mediated re-
sponse), while simultaneously increasing the half-lives of
pre-existing self peptide MHC I complexes at the plasma
membrane (for evasion of an NK cell-mediated re-
sponse). This suggests that ORFV like other large DNA
viruses (e.g. Herpesviruses) uses different evasion strat-
egies to interfere with antigen presentation at different
levels of MHC I processing.
Conclusion
We assume that the reduction of surface expressed
MHC I and the impaired structure and function of the
Golgi apparatus, which are possibly controlled by differ-
ent ORFV gene products, independently affect intracel-
lular transport and surface stability of MHC I and
cooperatively undermine immune recognition of ORFV-
infected cells by CTLs as well as NK cells. In view of the
fact that the immunity elicited by ORFV is short-lived,
and animals can be repeatedly infected [2], MHC I sub-
version may contribute to rescuing ORFV from host im-




The attenuated ORFV strain D1701-V was propagated
and titrated in Vero cells as described [36]. Virus inacti-
vation was achieved with 0.05% (v/v) β-Propiolactone
(Serva) by incubation at 37 °C for 4 h and maintaining
the pH-value of 7.6. After overnight incubation at 4 °C
the supernatant was collected by centrifugation and
plaque assays proved the successful virus inactivation.
Antibodies
The mouse mAb W6/32 specific for HLA-ABC also
recognizing simian MHC I [37] was used for flow cyto-
metry, confocal fluorescence microscopy and immuno-
precipitation. LY5.1 is a mAb recognizing MHC class I
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http://www.biomedcentral.com/1746-6148/8/114heavy chains of HLA-ABC (Acris). Antibodies specific
for Giantin, TGN46 and β-COP were purchased from
Abcam, the antibody against ß-actin from Sigma-Aldrich
. The mAb 13 C10 is directed against the 39 K major en-
velope protein of ORFV [38] and was a generous gift of
C. McInnes and P. Nettleton (MRI, Pentlands Science
Park, Penicuik, Scotland). As second antibodies we used
anti-mouse FITC-conjugated antibody (Dianova), anti-
mouse Alexa Fluor 488- and Alexa Fluor 555-conjugated
antibodies and anti-rabbit Alexa Fluor 488- and Alexa
Fluor 555-conjugated antibodies (Fisher Scientific, Invi-
trogen) and HRP-conjugated anti-rabbit IgG (Dianova).
Flow cytometry
Vero cells were infected with a m.o.i. of 1.0, harvested
and stained successively with primary antibody and
FITC-conjugated secondary antibody for 30 minutes at
4 °C. Brefeldin A (BFA, Sigma-Aldrich) was used in a
concentration of 10 μg ml-1, cytosine arabinoside (AraC,
Sigma-Aldrich) was added (40 μg ml-1) during virus in-
fection. For viable cell determination dead cells were
stained with 7-AAD (BD Bioscience) prior to FACS ana-
lyses using a FACSCalibur (BD Bioscience) and Cell-
Quest Pro (BD Bioscience).
RNA isolation and semi-quantitative reverse transcription
PCR
RNA kit (SurePrep True Total RNA Purification Kit,
Fisher Scientific) was used to isolate total RNA from
infected (m.o.i. 1.0) and non-infected Vero cells accord-
ing to the manufacturer's instructions. RNA was treated
with DNase (DNA-free, Ambion) and 300 ng were used
for RT-PCR. Specific RNA of MHC I and Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as a housekeeping
gene was amplified by RT-PCR according to the manufac-
turer's recommendation (OneStep RT-PCR Kit, Qiagen)
in a total volume of 10 μl, using GAPDH-specific primers
at an annealing temperature of 64 °C [39] or using MHC I
generic primers at an annealing temperature of 62 °C [40].
PCR products were taken during the linear phase of amp-
lification, separated by gel electrophoresis and the ampli-
con DNA band intensities were quantified using GelEval
1.32 software (FrogDance Software).
Immunofluorescence
Vero cells were grown and infected (m.o.i. 0.5) in cham-
ber slides (BD Biosciences) and fixed with 2% (v/v)
methanol-free formaldehyde (Pierce, Fisher Scientific) in
PBS and permeabilized with 0.2% (v/v) Triton-X100
(Sigma-Aldrich) in PBS. After 30 minutes blocking at
room temperature in 5% (v/v) FCS in PBS, all antibody
incubations were performed in PBS containing 1% (v/v)
FCS for 30 minutes at 37 °C. F-actin was stained with
Phalloidin-TRITC (Sigma-Aldrich), nuclei were stainedwith DAPI (1 μg ml-1, Sigma-Aldrich) before embedding
of slides in Mowiol-DABCO. Confocal microscopy was
performed with ApoTome confocal fluorescence micro-
scope (Axiovert 200 M; Zeiss) and arranged with Axio-
Vision Rel. 4.8 (Zeiss). The Pearson coefficient showing
degree of colocalization was determined using the pro-
gram CoLocalizer Express (CoLocalizer).Biosynthetic labelling and immunoprecipitation of
proteins
Cells were starved for one hour in methionine-cysteine
free Dulbecco’s modified Eagle’s medium (DMEM; Gibco)
supplemented with 4 mM L-glutamine and 1 mM Na-
Pyruvate, followed by incubation for additional 12 h in the
presence of 10.5 mCi ml-1 Trans-35 S-Label (MP Biomedi-
cals). Washed labelled cells were solubilised in PBS con-
taining 1% Triton- X100 (Sigma-Aldrich) on ice for 45
minutes. After centrifugation at 14.000 rpm for 5 minutes
the supernatants were used for immunoprecipitations at
4 °C overnight with anti MHC I mAb W6/32, which has
been coupled directly to cyanogen bromide-activated
sepharose (Amersham Life Sci.). Precipitates were digested
with 10 mU of Endo H (Sigma-Aldrich) for 12 h at 37 °C
and MHC I was eluted with 2.4 M urea, 2% SDS, 20% Gly-
cerine, 125 mM Tris (pH 6.8) for 5 minutes at 95 °C prior
to SDS-PAGE. Following electrophoresis fixed and dried
gels were exposed to X-ray films (Kodak).SDS-PAGE and western blot analysis
Non-infected and infected (m.o.i. 1.0) cells were dis-
solved with 1% (v/v) Triton- X100 (Sigma-Aldrich) in
PBS for 30 minutes at 4 °C. SDS-PAGE and Western
Blot were performed as reported [41]. All antibodies
were diluted in 1 x RotiBlock (Roth) and for enhanced
chemiluminescence (ECL) the substrate Immobilon
Western HRP (Millipore) was used. X-ray films for ECL
were purchased from Pierce (Fisher Scientific).Statistical analysis
Statistical significances were evaluated by One-way
ANOVA analysis (Figure 1) or by the T test (Figures 2
and 3) using GraphPad Prism 5 software (La Jolla).
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